Format

Send to

Choose Destination
Am J Hematol. 2008 Jun;83(6):491-7. doi: 10.1002/ajh.21183.

Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy.

Author information

1
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota55905., USA. tefferi.ayalew@mayo.edu

Abstract

The recent discovery of JAK2 and/or MPL mutations in polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) has had a major impact on how we diagnose and treat these disorders. For instance, the presence of a JAK2 mutation is now considered conditio sine qua non for the diagnosis of PV and the World Health Organization classification system has recently revised its diagnostic criteria for PV, ET, and PMF to include JAK2 and MPL mutations as clonal markers. From the standpoint of treatment, JAK-STAT is now identified as a legitimate target pathway for drug development in myeloproliferative neoplasms. Herein, I will first outline my views regarding current management in ET, PV, and PMF and then discuss emerging data on preclinical and clinical activity of anti-JAK2 small molecule drugs. Am. J. Hematol., 2008.

PMID:
18429051
DOI:
10.1002/ajh.21183
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center